Physician profile
David J Benjamin
NPI 1821450396
$68,052.30
in general payments reported to CMS, 2019-2025
25 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.84 · 2023: $5,714 · 2024: $27K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $18K · Consulting Fee: $11K · Honoraria: $6,224 · Food and Beverage: $4,350 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,910.00 |
| Travel and Lodging | $17,556.22 |
| Consulting Fee | $10,689.50 |
| Honoraria | $6,223.50 |
| Food and Beverage | $4,349.75 |
| Education | $300.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Healthcare Kgaa | $27,436.21 | 2025 | |
| Merck Sharp & Dohme LLC | $19,520.29 | 2022-2025 | Lynparza, Keytruda, Welireg |
| Pfizer INC. | $5,410.02 | 2024 | |
| Exelixis INC. | $2,974.76 | 2023-2024 | Cabometyx |
| Emd Serono, INC. | $2,440.22 | 2024-2025 | |
| Glaxosmithkline, LLC. | $2,195.28 | 2025 | Jemperli |
| Eisai INC. | $1,760.38 | 2023-2024 | |
| Astellas Pharma Global Development | $1,727.07 | 2024 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $1,407.93 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $1,296.91 | 2024 | |
| Janssen Scientific Affairs, LLC | $954.43 | 2024 | Erleada, Akeega, Balversa |
| Janssen Biotech, INC. | $220.77 | 2024 | Darzalex |
| Bayer Healthcare LLC | $149.78 | 2025 | |
| Fennec Pharmaceuticals, INC. | $101.26 | 2025 | Fyarro |
| Caris Mpi, INC. | $92.68 | 2025 | Mi Cancer Seek |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $64.83 | 2023-2024 | Lynparza |
| Daiichi Sankyo INC. | $58.85 | 2023-2024 | Enhertu |
| Astellas Pharma US INC | $50.43 | 2024-2025 | Xospata, Xtandi |
| Tempus Ai, INC | $45.05 | 2024 | |
| Puma Biotechnology, INC. | $27.56 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.93 | 2024 | |
| Incyte Corporation | $24.11 | 2023 | Jakafi |
| Tersera Therapeutics LLC | $23.39 | 2023 | Quzyttir |
| Abbvie INC. | $22.70 | 2024 | |
| Rigel Pharmaceuticals, INC. | $22.46 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.